Mcclain Value Management Has Increased By $803,300 Its Alleghany (Y) Position; Shorts at Rxi Pharmaceuticals (RXII) Raised By 14.87%

March 13, 2018 - By Winifred Garcia

Rxi Pharmaceuticals Corporation (NASDAQ:RXII) had an increase of 14.87% in short interest. RXII’s SI was 194,700 shares in March as released by FINRA. Its up 14.87% from 169,500 shares previously. With 93,600 avg volume, 2 days are for Rxi Pharmaceuticals Corporation (NASDAQ:RXII)’s short sellers to cover RXII’s short positions. The SI to Rxi Pharmaceuticals Corporation’s float is 10.11%. The stock decreased 13.03% or $0.49 during the last trading session, reaching $3.27. About 179,872 shares traded. RXi Pharmaceuticals Corporation (NASDAQ:RXII) has declined 75.22% since March 13, 2017 and is downtrending. It has underperformed by 91.92% the S&P500.

Mcclain Value Management Llc increased Alleghany Corp (Y) stake by 22.24% reported in 2017Q3 SEC filing. Mcclain Value Management Llc acquired 1,450 shares as Alleghany Corp (Y)’s stock declined 10.28%. The Mcclain Value Management Llc holds 7,969 shares with $4.42M value, up from 6,519 last quarter. Alleghany Corp now has $9.68 billion valuation. The stock increased 0.08% or $0.5 during the last trading session, reaching $628.99. About 14,709 shares traded. Alleghany Corporation (NYSE:Y) has risen 7.94% since March 13, 2017 and is uptrending. It has underperformed by 8.76% the S&P500.

Mcclain Value Management Llc decreased Enanta Pharmaceuticals Inc (NASDAQ:ENTA) stake by 27,233 shares to 38,062 valued at $1.78M in 2017Q3. It also reduced Donnelley Financial Solutions stake by 19,122 shares and now owns 173,829 shares. Fnfv Group Of Fidelity Nationa (NYSE:FNFV) was reduced too.

Since February 27, 2018, it had 0 insider purchases, and 1 insider sale for $323,501 activity. The insider LAVIN WILLIAM K sold 530 shares worth $323,501.

Investors sentiment decreased to 1.07 in Q3 2017. Its down 0.07, from 1.14 in 2017Q2. It turned negative, as 28 investors sold Y shares while 89 reduced holdings. 34 funds opened positions while 99 raised stakes. 12.56 million shares or 0.02% more from 12.56 million shares in 2017Q2 were reported. 50,957 are owned by Sumitomo Mitsui Tru Holdings. 1,486 were reported by Profund Ltd Liability Company. Alabama-based Retirement Systems Of Alabama has invested 0.09% in Alleghany Corporation (NYSE:Y). Nomura Hldg has 8,100 shares for 0.01% of their portfolio. Mcrae Cap Inc invested 0.17% of its portfolio in Alleghany Corporation (NYSE:Y). British Columbia Invest Mngmt Corp stated it has 5,965 shares. Macquarie Gru Limited reported 1,100 shares. State Of Alaska Department Of Revenue has invested 0.05% in Alleghany Corporation (NYSE:Y). Robeco Institutional Asset Mngmt Bv reported 0.17% in Alleghany Corporation (NYSE:Y). Citigroup invested in 5,639 shares or 0% of the stock. United Ser Automobile Association has 730 shares for 0% of their portfolio. Cap One National Association invested 0.02% of its portfolio in Alleghany Corporation (NYSE:Y). Barclays Public Limited Company stated it has 0% of its portfolio in Alleghany Corporation (NYSE:Y). 3,121 are held by Proshare Advisors Ltd Llc. Lafayette Invests invested in 3.52% or 17,084 shares.

Among 2 analysts covering Alleghany (NYSE:Y), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Alleghany had 3 analyst reports since June 16, 2016 according to SRatingsIntel. Citigroup upgraded it to “Buy” rating and $43 target in Thursday, June 16 report. The stock of Alleghany Corporation (NYSE:Y) has “Hold” rating given on Thursday, February 22 by JMP Securities. The rating was upgraded by JMP Securities to “Buy” on Monday, September 11.

RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. The company has market cap of $7.75 million. It develops therapies based on its self-delivering RNAi platform; and Samcyprone topical immunomodulatory. It currently has negative earnings. The companyÂ’s clinical development programs include RXI-109, an sd-rxRNA compound, which is in Phase II clinical trial for preventing or reducing dermal scarring following scar revision surgery of an existing hypertrophic scar; and in Phase I/II clinical trial for treating retinal scarring, as well as in discovery stage for the treatment of corneal scarring.